















Keynote Speaker, AIDS Day Commemoration, Austin, Texas, 2011  
Consultation on Advancing HIV Incidence Surveillance, Centers for Disease Control and  
Prevention, Atlanta, Georgia, 2011



International AIDS Society (IAS) Controversies in HIV Cure Research, Rome Italy, 2011

American Society for Microbiology Conference of Undergraduate Educators, Baltimore, Maryland, 2011

Division of AIDS Prevention Sciences Program Potential Biomarkers for HIV Incidence Assay Development, Bethesda, Maryland, 2011

IAS Pre-Conference Workshop: Towards a Cure: HIV Reservoirs and Strategies to Control Them, Vienna, Austria, 2010

Mount Sinai School of Medicine Infectious Diseases Grand Rounds, New York, New York, 2010

National Institute of Infectious Disease, Tokyo, Japan, 2010

Nagoya University, Nagoya, Japan, 2010

SAIC Translational Research Seminar Series, Frederick, Maryland, 2010

17th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 2010

Keynote Speaker, Johns Hopkins Biotechnology, Center for Talented Youth, Rockville, Maryland, 2010

Division of AIDS, NIAID, Bethesda, Maryland, 2010

Aaron Diamond AIDS Research Center, New York, New York, 2009

Center for Cancer Research Grand Rounds, Bethesda, Maryland, 2009

NIH Clinical Grand Rounds, Bethesda, Maryland, 2009

XVII International HIV Drug Resistance Workshop, Sanibel Island, Florida, 2009

Division of AIDS, NIAID, Bethesda, Maryland, 2009

Workshop on Eliminating Viral Persistence and Eradicating HIV Infection, Washington, D.C., 2008

XVI International HIV Drug Resistance Workshop, Sitges, Spain, 2008

Grand Rounds, Washington Hospital Center, Washington, D.C., 2008

NIAID Grand Rounds, NIH, Bethesda, Maryland, 2007

Viral Genomics Workshop, Broad Institute, MIT/Harvard, Cambridge, Massachusetts, 2007

Cold Spring Harbor Laboratory Meeting on Retroviruses, Cold Spring Harbor, New York, 2007

13th Conference on Retroviruses and Opportunistic Infections, Denver, Colorado, 2007

17th Annual HIV Symposium, Nassau University Medical Center, East Meadow, New York, 2006

Pennsylvania/Mid-Atlantic AIDS Education and Training Center, Fairfax, Virginia, 2006

HIV Advanced Clinical Update AIDS Education and Training Center, Fairfax, Virginia, 2005-2006

PACT Project Neighborhood Lecture Series, Washington, D.C., 2005

NCI-Frederick Lecture Series, Frederick, Maryland, 2005

XIV International HIV Drug Resistance Workshop, Quebec City, Canada, 2005

Cold Spring Harbor Laboratory Meeting on Retroviruses, Cold Spring Harbor, New York, 2005

NIAID Grand Rounds, Bethesda, Maryland, 2001-2005

XIII International HIV Drug Resistance Workshop, Tenerife, Spain, 2004

Cold Spring Harbor Laboratory Meeting on Retroviruses, Cold Spring Harbor, New York, 2004

DOD-TACC Joint Meeting, Bethesda, Maryland, 2004

NIH Demystifying Medicine Lecture Series, Bethesda, Maryland, 2004

XII International HIV Drug Resistance Workshop, Cabo St. Lucas, Mexico, 2004

10th International Workshop on HIV Dynamics and Evolution, Lake Arrowhead, California, 2003

Cold Spring Harbor Laboratory Meeting on Retroviruses, Cold Spring Harbor, New York, 2003

Washington Hospital Center Infectious Diseases Lecture Series, Washington, D.C., 2002

NIAID Laboratory of Immunoregulation Lecture Series, Bethesda, Maryland, 2002

NIAID Grand Rounds, Bethesda, Maryland, 2001-2002

NCI-Frederick Lecture Series, Frederick, Maryland, 2001

**FRANK MALDARELLI, M.D., PH.D.**

BIBLIOGRAPHY

Peer-Reviewed Research Publications:

1. Lau CY, Adan MA, **Maldarelli F**. Why the HIV Reservoir Never Runs Dry: Clonal Expansion and the Characteristics of HIV-Infected Cells Challenge Strategies to Cure and Control HIV Infection. *Viruses*. 2021 Dec 14;13(12):2512. doi: 10.3390/v13122512. PMID: 34960781
2. Coffin JM, Bale MJ, Wells D, Guo S, Luke B, Zerbato JM, Sobolewski MD, Sia T, Shao W, Wu X, **Maldarelli F**, Kearney MF, Mellors JW, Hughes SH. Integration in oncogenes plays only a minor role in determining the in vivo distribution of HIV integration sites before or during suppressive antiretroviral therapy. *PLoS Pathog*. 2021 Apr 7;17(4):e1009141. doi: 10.1371/journal.ppat.1009141. eCollection 2021 Apr. PMID: 33826675
3. Patro SC, Niyongabo A, **Maldarelli F**, Kearney MF. New Approaches to Multi-Parametric HIV-1 Genetics Using Multiple Displacement Amplification: Determining the What, How, and Where of the HIV-1 Reservoir Viruses. 2021 Dec 10;13(12):2475. doi: 10.3390/v13122475. PMID: 34960744
4. Mitchell JL, Pollara J, Dietze K, Edwards RW, Nohara J, N'guessan KF, Zemil M, Buranapraditkun S, Takata H, Li Y, Muir R, Kroon E, Pinyakorn S, Jha S, Manasnayakorn S, Chottanapund S, Thantiworasit P, Prueksakaew P, Ratnaratorn N, Nuntapinit B, Fox L, Tovnanabutra S, Paquin-Proulx D, Wiczorek L, Polonis VR, **Maldarelli F**, Haddad EK, Phanuphak P, Sacdalan CP, Rolland M, Phanuphak N, Ananworanich J, Vasana S, Ferrari G, Trautmann L; RV254 and RV304 Study Groups. Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. *J Clin Invest*. 2022 Jan 4;132(1):e150937. doi: 10.1172/JCI150937. PMID: 34762600
5. Boyer PL, Rehm CA, Sneller MC, Mican J, Caplan MR, Dewar R, Ferris AL, Clark P, Johnson A, **Maldarelli F**, Hughes SH. A Combination of Amino Acid Mutations Leads to Resistance to Multiple Nucleoside Analogs in Reverse Transcriptases from HIV-1 Subtypes B and C. *Antimicrob Agents Chemother*. 2021 Nov 1;AAC0150021. doi: 10.1128/AAC.01500-21. Online ahead of print. PMID: 34723625
6. Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong M, Lambotte O, Lamplough R, Ndung'u T, Sugarman J, Tiemessen CT, Vandekerckhove L, Lewin SR; International AIDS Society (IAS) Global Scientific Strategy working group. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. *Nat Med*. 2021 Dec;27(12):2085-2098. doi: 10.1038/s41591-021-01590-5. Epub 2021 Dec 1. PMID: 34848888.
7. Gatechompol S, Zheng L, Bao Y, Avihingsanon A, Kerr SJ, Kumarasamy N, Hakim JG, **Maldarelli F**, Gorelick RJ, Welker JL, Lifson JD, Hosseinipour MC, Eron JJ,

- Ruxrungtham K. Prevalence and risk of residual viremia after ART in low- and middle-income countries: A cross-sectional study. *Medicine (Baltimore)*. 2021 Sep 3;100(35):e26817. doi: 10.1097/MD.00000000000026817. PMID: 34477118 Free PMC article.
8. Merati TP, Karyana M, Tjitra E, Kosasih H, Aman AT, Alisjahbana B, Lokida D, Arlinda D, Maldarelli F, Neal A, Arif M, Gasem MH, Lukman N, Sudarmono P, Lau CY, Hadi U, Lisdawati V, Wulan WN, Lane HC, Siddiqui S. Prevalence of HIV Infection and Resistance Mutations in Patients Hospitalized for Febrile Illness in Indonesia. *Am J Trop Med Hyg*. 2021 Aug 30;105(4):960-965. doi: 10.4269/ajtmh.20-1595. PMID: 34460416
  9. Boltz VF, Ceriani C, Rausch JW, Shao W, Bale MJ, Keele BF, Hoh R, Milush JM, Deeks SG, **Maldarelli F**, Kearney MF, Coffin JM. CpG Methylation Profiles of HIV-1 Pro-Viral DNA in Individuals on ART. *Viruses*. 2021 Apr 29;13(5):799. doi: 10.3390/v13050799. PMID: 33946976
  10. Kroon, E.D.M.B., J. Ananworanich, A. Pagliuzza, A. Rhodes, N. Phanuphak, L. Trautmann, J.L. Mitchell, M. Chintanaphol, J. Intasan, S. Pinyakorn, K. Benjapornpong, J.J. Chang, D.J. Colby, N. Chomchey, J.L.K. Fletcher, K. Eubanks, H. Yang, J. Kapson, A. Dantanarayana, S. Tennakoon, R.J. Gorelick, **F. Maldarelli**, M.L. Robb, J.H. Kim, S. Spudich, N. Chomont, P. Phanuphak, S.R. Lewin, M.S. de Souza, and SEARCH 019 and RV254 Study Teams. 2020. A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection. *J. Virus Erad.* **6**:100004. PMCID: [PMC7646672](#).
  11. Shao, W., V.F. Boltz, J. Hattori, M.J. Bale, **F. Maldarelli**, J.M. Coffin, and M.F. Kearney. 2020. HIV-DRLink: A tool for reporting linked HIV-1 drug resistance mutations in large single-genome datasets using the Stanford HIV Database. *AIDS Res. Hum. Retroviruses* **36**:942-947. PMID: [32683881](#).
  12. Elbezanti, W., A. Lin, A. Schirling, A. Jackson, M. Marshall, R. Van Duyne, **F. Maldarelli**, L. Sardo, and Z. Klase. 2020. Benzodiazepines drive alteration of chromatin at the integrated HIV-1 LTR. *Viruses* **12**:E191. PMCID: [PMC7077212](#).
  13. Mitchell, J.L., H. Takata, R. Muir, D.J. Colby, E. Kroon, T.A. Crowell, C. Sacdalan, S. Pinyakorn, S. Pattamaswin, K. Benjapornpong, R. Trichavaroj, R.L. Tressler, L. Fox, V.R. Polonis, D.L. Bolton, **F. Maldarelli**, S.R. Lewin, E.K. Haddad, P. Phanuphak, M.L. Robb, N.L. Michael, M. de Souza, N. Phanuphak, J. Ananworanich, and L. Trautmann. 2020. Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption. *J. Clin. Invest.* **Feb 4**:130597. PMCID: [PMC7260031](#).
  14. Anderson, E.M., F.R. Simonetti, R.J. Gorelick, S. Hill, M.A. Gouzoulis, J. Bell, C. Rehm, L. Pérez, E. Boritz, X. Wu, D. Wells, S.H. Hughes, V. Rao, J.M. Coffin, M.F. Kearney, and **F. Maldarelli**. 2020. Dynamic shifts in the HIV proviral landscape during long term combination antiretroviral therapy: Implications for persistence and control of HIV infections. *Viruses* **12**:E136. PMCID: [PMC7077288](#).
  15. Reid E.G., A. Suazo, S.Y. Lensing, D.P. Dittmer, R.F. Ambinder, **F. Maldarelli**, R.J. Gorelick, D. Abouafia, R. Mitsuyasu, M.A. Dickson, W. Wachsman for the AIDS Malignancy Consortium. 2020. Pilot Trial AMC-063: Safety and efficacy of bortezomib in AIDS-associated Kaposi sarcoma. *Clin. Cancer Res.* **26**:558-565. PMCID: [PMC7034393](#).

16. Patro, S.C., L.D. Brandt, M.J. Bale, E.K. Halvas, K.W. Joseph, W. Shao, X. Wu, S. Guo, B. Murrell, A. Wiegand, J. Spindler, C. Raley, C. Hautman, M. Sobolewski, C.M. Fennessey, W.-S. Hu, B. Luke, J.M. Hasson, A. Niyongabo, A.A. Capoferri, B.F. Keele, J. Milush, R. Hoh, S.G. Deeks, **F. Maldarelli**, S.H. Hughes, J.M. Coffin, J.W. Rausch, J.W. Mellors, and M.F. Kearney. 2019. Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors Proc. Natl. Acad. Sci. USA **116**:25891-25899. PMID: [PMC6925994](https://pubmed.ncbi.nlm.nih.gov/3125994/).

17. Hataye, J.M., J.P. Casazza, K. Best, C.J. Liang, T. Immonen, D.R. Ambrozak, S. Darko, A.R. Henry, F. Laboune, **F. Maldarelli**, D.C. Douek, N.W. Hengartner, T. Yamamoto, B.F. Keele, A.S. Perelson, and R.A. Koup. 2019. Principles governing establishment versus collapse of HIV-1 cellular spread. *Cell Host Microbe* **26**:748-763.
18. Musick, A., J. Spindler, E. Boritz, L. Pérez, D. Crespo-Vélez, S.C. Patro, M.D. Sobolewski, M.J. Bale, C. Reid, B.F. Keele, A. Capoferri, W. Shao, A. Wiegand, F.R. Simonetti, J.W. Mellors, S.H. Hughes, J.M. Coffin, **F. Maldarelli**, and M.F. Kearney. 2019. HIV infected T cells can proliferate *in vivo* without inducing expression of the integrated provirus. *Front. Microbiol.* **10**:2204. PMID: [PM6781911](https://pubmed.ncbi.nlm.nih.gov/31211111/).
19. Wonderlich, E.R., K. Subramanian, B. Cox, A. Wiegand, C. Lackman-Smith, M.J. Bale, M. Stone, R. Hoh, M.F. Kearney, **F. Maldarelli**, S. Deeks, M.P. Busch, R.G. Ptak, and D.A. Kulpa. 2019. Effector memory differentiation increases detection of replication-competent HIV-1 in resting CD4+ T cells from virally suppressed individuals. *PLOS Pathog.* **15**: e1008074. PMID: [PM6812841](https://pubmed.ncbi.nlm.nih.gov/31211111/).
20. Bozzi, G., F.R. Simonetti, S.A. Watters, E.M. Anderson, M. Gouzoulis, M.F. Kearney, P. Rote, C. Lange, W. Shao, R. Gorelick, B. Fullmer, S. Kumar, S. Wank, S. Hewitt, D.E. Kleiner, J. Hattori, M.J. Bale, S. Hill, J. Bell, C. Rehm, Z. Grossman, R. Yarchoan, T. Uldrick, and **F. Maldarelli**. 2019. No evidence of ongoing HIV-1 replication in tissue compartments during cART. *Sci. Adv.* **5**:eaav2045. PMID: [PM6760922](https://pubmed.ncbi.nlm.nih.gov/31211111/).
21. Grossman, Z., B. Avidor, S. Girshengoren, E. Katchman, **F. Maldarelli**, and D. Turner. 2019. Transmission dynamics of HIV subtype A in Tel Aviv, Israel: Implications for HIV spread and eradication. *Open Forum Infect. Dis.* **6**:ofz304. PMID: [PM6657966](https://pubmed.ncbi.nlm.nih.gov/31211111/).
22. Winchester, N.E., **F. Maldarelli**, Y. Mejia, N. Dee, R. Dewar, E. Laidlaw, S.S. Kuriakose, P. Stoll, M. Proshan, H.C. Lane, and A.K. Pau. 2019. 8-Day inpatient directly observed therapy for ART failure: A tool for preventing unnecessary ART changes and optimizing adherence support. *Clin. Infect. Dis.* **Jul 11**:ciz590. PMID: [PM67319057](https://pubmed.ncbi.nlm.nih.gov/31211111/).
23. Coffin, J.M., D.W. Wells, J.M. Zerbato, J.D. Kuruc, S. Guo, B.T. Luke, J.J. Eron, M. Bale, J. Spindler, F.R. Simonetti, S. Hill, M.F. Kearney, **F. Maldarelli**, X. Wu, J.W. Mellors, and S.H. Hughes. 2019. Clones of infected cells arise early in HIV-infected individuals. *JCI Insight* **4**:128432. PMID: [PM6629130](https://pubmed.ncbi.nlm.nih.gov/31211111/).
24. Gibson, K.M., M.C. Steiner, S. Kassaye, **F. Maldarelli**, Z. Grossman, M. Perez-Losada, and K.A. Crandall. 2019. A 28-year history of HIV-1 drug resistance and transmission in Washington, DC. *Front. Microbiol.* **10**:369. PMID: [PM6418020](https://pubmed.ncbi.nlm.nih.gov/31211111/).
25. Fennessey, C.M., C. Camus, T.T. Immonen, C. Reid, **F. Maldarelli**, J.D. Lifson, and B.F. Keele. 2019. Low-level alternative tRNA priming of reverse transcription of HIV-1 and SIV *in vivo*. *Retrovirology* **16**:11. PMID: [PM6450007](https://pubmed.ncbi.nlm.nih.gov/31211111/).
26. Reid, E.G., D. Looney, **F. Maldarelli**, A. Noy, D. Henry, D. Aboulafia, J.C. Ramos, J. Sparano, R.F. Ambinder, J. Lee, E. Cesarman, S. Yahyaei, R. Mitsuyasu, and W. Wachsman. 2018. Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas. *Blood Adv.* **2**:3618-3626. PMID: [PM6306883](https://pubmed.ncbi.nlm.nih.gov/31211111/).

27. Pastrana, D.V., A. Peretti, N.L. Welch, C. Borgogna, C. Olivero, R. Badolato, L.D. Notarangelo, M. Gariglio, P.C. FitzGerald, C.E. McIntosh, J. Reeves, G.J. Starrett, V. Bliskovsky, D. Velez, I. Brownell, R. Yarchoan, K.M. Wyvill, T.S. Uldrick, **F. Maldarelli**, A. Lisco, I. Sereti, C.M. Gonzalez, E.J. Androphy, A.A. McBride, K. Van Doorslaer, F. Garcia, I. Dvoretzky, J.S. Liu, J. Han, P.M. Murphy, D.H. McDermott, and C.B. Buck. 2018. Metagenomic discovery of 83 new human papillomavirus types in patients with immunodeficiency. *mSphere* **3**:e00645-18. PMID: [PMC6291628](#).
28. Grossman, Z., S.V. Rico, K. Cone, W. Shao, C. Rehm, S. Jones, G. Bozzi, S. Dean, R. Dewar, T. Rehman, J. Purdy, C. Hadigan, A.K. Pau, and **F. Maldarelli**. 2018. Early presence of HIV-1 subtype C in Washington, D.C. *AIDS Res. Hum. Retroviruses* **34**:680-684. PMID: [PMC6080110](#).
29. George, J.M., S.S. Kuriakose, N. Dee, P. Stoll, T. Lalani, R. Dewar, M.A. Khan, M.T. Rehman, Z. Grossman, **F. Maldarelli**, and A.K. Pau. 2018. Rapid development of high-level resistance to dolutegravir with emergence of T97A mutation in 2 treatment-experienced individuals with baseline partial sensitivity to dolutegravir. *Open Forum Infect. Dis.* **5**:ofy221. PMID: [PMC6172925](#).
30. Anderson, E.M., and **F. Maldarelli**. 2018. Quantification of HIV DNA using droplet digital PCR techniques. *Curr. Protoc. Microbiol.* **51**:e62. PMID: [PMC6209535](#).
31. Anderson, E.M., and **F. Maldarelli**. 2018. The role of integration and clonal expansion in HIV infection: Live long and prosper. *Retrovirology* **15**:71. PMID: [PMC6199739](#).
32. Colby, D.J., L. Trautmann, S. Pinyakorn, L. Leyre, A. Pagliuzza, E. Kroon, M. Rolland, H. Takata, S. Buranapraditkun, J. Intasan, N. Chomchey, R. Muir, E.K. Haddad, S. Tovanabutra, S. Ubolyam, D.L. Bolton, B.A. Fullmer, R.J. Gorelick, L. Fox, T.A. Crowell, R. Trichavaroj, R. O'Connell, N. Chomont, J.H. Kim, N.L. Michael, M.L. Robb, N. Phanuphak, J. Ananworanich, and **RV411 Study Group**. 2018. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. *Nat. Med.* **24**:923-926. PMID: [PMC6092240](#).
33. Paredes, R., P.L. Tzou, G. van Zyl, G. Barrow, R. Camacho, S. Carmona, P.M. Grant, R.K. Gupta, R.L. Hamers, P.R. Harrigan, M.R. Jordan, R. Kantor, D.A. Katzenstein, D.R. Kuritzkes, **F. Maldarelli**, D. Otelea, C.L. Wallis, J.M. Schapiro, and R.W. Shafer. 2017. Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. *PLoS ONE* **12**:e0181357. PMID: [PMC5533429](#).
34. Kearney, M.F., A. Wiegand, W. Shao, W.R. McManus, M.J. Bale, B. Luke, **F. Maldarelli**, J.W. Mellors, and J.M. Coffin. 2017. Ongoing HIV replication during ART reconsidered. *Open Forum Infect. Dis.* **4**:ofx173. PMID: [PMC6172598](#).
35. Brooks, K.M., K.L. Garrett, S.S. Kuriakose, J.M. George, G. Balba, B. Bailey, M. Anderson, H.C. Lane, **F. Maldarelli**, and A.K. Pau. 2017. Decreased absorption of dolutegravir and tenofovir disoproxil fumarate, but not emtricitabine, in an HIV-infected patient following oral and jejunostomy-tube administration. *Pharmacotherapy* **37**:e82-e89. PMID: [PMC5559318](#).

36. Watters, S.A., P. Mlcochova, **F. Maldarelli**, N. Goonetilleke, D. Pillay, and R.K. Gupta. 2016. Sequential CCR5-Tropic HIV-1 Reactivation from distinct cellular reservoirs following perturbation of elite control. *PLoS ONE* **11**:e0158854. PMID: [PMC4942039](https://pubmed.ncbi.nlm.nih.gov/2642039/).
37. Simonetti, F.R., M.D. Sobolewski, E. Fyne, W. Shao, J. Spindler, J. Hattori, E.M. Anderson, S.A. Watters, S. Hill, X. Wu, D. Wells, L. Su, B.T. Luke, E.K. Halvas, G. Besson, K.J. Penrose, Z. Yang, R.W. Kwan, C. Van Waes, T. Uldrick, D.E. Citrin, J. Kovacs, M.A. Polis, C.A. Rehm, R. Gorelick, M. Piatak, B.F. Keele, M.F. Kearney, J.M. Coffin, S.H. Hughes, J.W. Mellors, and **F. Maldarelli**. 2016. Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo. *Proc. Natl. Acad. Sci. USA* **113**:1883-1888. PMID: [PMC4763755](https://pubmed.ncbi.nlm.nih.gov/2673755/).
38. Shao, W., J. Shan, M.F. Kearney, X. Wu, **F. Maldarelli**, J.W. Mellors, B. Luke, J.M. Coffin, and S.H. Hughes. 2016. Retrovirus Integration Database (RID): A public database for retroviral insertion sites into host genomes. *Retrovirology* **13**:47. PMID: [PMC4932684](https://pubmed.ncbi.nlm.nih.gov/26932684/).
39. Polizzotto, M.N., T.S. Uldrick, K.M. Wyvill, K. Aleman, C.J. Peer, M. Bevans, I. Sereti, **F. Maldarelli**, D. Whitby, V. Marshall, P.H. Goncalves, V. Khetani, W.D. Figg, S.M. Steinberg, J.B. Zeldis, and R. Yarchoan. 2016. Pomalidomide for symptomatic Kaposi's sarcoma in people with and without HIV infection: A phase I/II study. *J. Clin. Oncol.* **34**:4125-4131. PMID: [PMC5477825](https://pubmed.ncbi.nlm.nih.gov/265477825/).
40. Mikula, J.M., M.M. Manion, **F. Maldarelli**, L.M. Suarez, J.F. Norman-Wheeler, A.G. Ober, R.L. Dewar, J.B. Kopp, H.C. Lane, and A.K. Pau. 2016. Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy. *Antivir. Ther.* **21**:553-558. PMID: [PMC5016206](https://pubmed.ncbi.nlm.nih.gov/265016206/).
41. Kassaye, S.G., Z. Grossman, M. Balamane, B. Johnston-White, C. Liu, P. Kumar, M. Young, M.C. Sneller, I. Sereti, R. Dewar, C. Rehm, W. Meyer, 3rd, R. Shafer, D. Katzenstein, and **F. Maldarelli**. 2016. Transmitted HIV drug resistance is high and long-standing in metropolitan Washington, DC. *Clin. Infect. Dis.* **63**:836-843. PMID: [PMC4996138](https://pubmed.ncbi.nlm.nih.gov/264996138/).
42. Desimmie, B.A., R.C. Burdick, T. Izumi, H. Doi, W. Shao, W.G. Alvord, K. Sato, Y. Koyanagi, S. Jones, E. Wilson, S. Hill, **F. Maldarelli**, W.S. Hu, and V.K. Pathak. 2016. APOBEC3 proteins can copackage and comutate HIV-1 genomes. *Nucleic Acids Res.* **44**:7848-7865. PMID: [PMC5027510](https://pubmed.ncbi.nlm.nih.gov/265027510/).
43. Boritz, E.A., S. Darko, L. Swazek, G. Wolf, D. Wells, X. Wu, A.R. Henry, F. Laboune, J. Hu, D. Ambrozak, M.S. Hughes, R. Hoh, J.P. Casazza, A. Vostal, D. Bunis, K. Nganou-Makamdop, J.S. Lee, S.A. Migueles, R.A. Koup, M. Connors, S. Moir, T. Schacker, **F. Maldarelli**, S.H. Hughes, S.G. Deeks, and D.C. Douek. 2016. Multiple origins of virus persistence during natural control of HIV infection. *Cell* **166**:1004-1015. PMID: [PMC4983216](https://pubmed.ncbi.nlm.nih.gov/264983216/).
44. Boltz, V.F., J. Rausch, W. Shao, J. Hattori, B. Luke, **F. Maldarelli**, J.W. Mellors, M.F. Kearney, and J.M. Coffin. 2016. Ultrasensitive single-genome sequencing: Accurate, targeted, next generation sequencing of HIV-1 RNA. *Retrovirology* **13**:87. PMID: [PMC5175307](https://pubmed.ncbi.nlm.nih.gov/265175307/).

45. Asher, I., K.M. Guri, D. Elbirt, S.R. Bezalel, **F. Maldarelli**, O. Mor, Z. Grossman, and Z.M. Stoecker. 2016. Characteristics and outcome of patients diagnosed with HIV at older age. *Medicine (Baltimore)* **95**:e2327.
46. Simonetti, F.R., M.D. Sobolewski, E. Fyne, W. Shao, J. Spindler, J. Hattori, E.M. Anderson, S.A. Watters, S. Hill, X. Wu, D. Wells, L. Su, B.T. Luke, E.K. Halvas, G. Besson, K.J. Penrose, Z. Yang, R.W. Kwan, C. Van Waes, T. Uldrick, D. Citrin, J. Kovacs, M.A. Polis, C.A. Rehm, R. Gorelick, M. Piatak, B.F. Keele, M.F. Kearney, J.M. Coffin, S.H. Hughes, J.W. Mellors, and **F. Maldarelli**. 2016. Clonally expanded CD4<sup>+</sup> T cells can produce infectious HIV-1 in vivo. *Proc. Natl. Acad. Sci. USA* **113**:1883-1888. PMID: [PMC4763755](#).
47. **Maldarelli, F.** 2016. The role of HIV integration in viral persistence: No more whistling past the proviral graveyard. *J. Clin. Invest.* **126**:438-447. PMID: [PMC4731194](#).
48. Asher, I., K.M. Guri, D. Elbirt, S.R. Bezalel, **F. Maldarelli**, O. Mor, Z. Grossman, and Z.M. Stoecker. 2016. Characteristics and outcome of patients diagnosed with HIV at older age. *Medicine* **95**:e2327. PMID: [PMC4706254](#).
49. **Maldarelli, F.** 2015. HIV-infected cells are frequently clonally expanded after prolonged antiretroviral therapy: Implications for HIV persistence. *J. Virus. Erad.* **1**:237-244. PMID: [PMC4946654](#).
50. Valcour, V.G., S.S. Spudich, N. Sailasuta, N. Phanuphak, S. Lerdlum, J.L. Fletcher, E.D. Kroon, L.L. Jagodzinski, I.E. Allen, C.L. Adams, P. Prueksakaew, B.M. Slike, J.M. Hellmuth, J.H. Kim, J. Ananworanich J, and **SEARCH 010/RV 254 Study Group**. 2015. Neurological response to cART vs. cART plus integrase inhibitor and CCR5 antagonist initiated during acute HIV. *PLoS ONE* **10**:e0142600. PMID: [PMC4640512](#).
51. Grossman, Z., B. Avidor, Z. Mor, M. Chowers, I. Levy, E. Shahar, K. Riesenber, Z. Stoecker, S. Maayan, W. Shao, M. Lorber, K. Olstein-Pops, D. Elbirt, H. Elinav, I. Asher, D. Averbuch, V. Istomin, B.S. Gottesman, E. Kedem, S. Girshengorn, Z. Kra-Oz, Y. Shemer Avni, S. Radian Sade, D. Turner, and **Maldarelli, F.** 2015. A population-structured HIV epidemic in Israel: Roles of risk and ethnicity. *PLoS ONE* **10**:e0135061. PMID: [PMC4547742](#).
52. De Ravin, S.S., J.T. Gray, R.E. Throm, J. Spindler, M. Kearney, X. Wu, J.M. Coffin, S.H. Hughes, **F. Maldarelli**, B.P. Sorrentino, and H.L. Malech. 2014. False-positive HIV PCR test following ex vivo lentiviral gene transfer treatment of X-linked severe combined immunodeficiency vector. *Mol. Ther.* **22**:244-245.
53. Shao, W., M.F. Kearney, V.F. Boltz, J.E. Spindler, J.W. Mellors, **F. Maldarelli**, and J.M. Coffin. 2014. PAPNC, a novel method to calculate nucleotide diversity from large scale next generation sequencing data. *J. Virol. Methods* **203C**:73-80. PMID: [PMC4104926](#).
54. **Maldarelli, F.**, X. Wu, L. Su, F.R. Simonetti, W. Shao, S. Hill, J. Spindler, A.L. Ferris, J.W. Mellors, M.F. Kearney, J.M. Coffin, and S.H. Hughes. 2014. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. *Science* **345**:179-183. PMID: [PMC4262401](#).
55. Lau, C.Y., **F. Maldarelli**, W.C. Eckelman, and R.D. Neumann. 2014. Rational development of radiopharmaceuticals for HIV-1. *Nucl. Med. Biol.* **41**:299-308. PMID: [PMC3954989](#).



56. Klase, Z., V.S. Yedavalli, L. Houzet, M. Perkins, **F. Maldarelli**, J. Brenchley, K. Strebel, P. Liu, and K.T. Jeang. 2014. Activation of HIV-1 from latent infection via synergy of RUNX1 inhibitor Ro5-3335 and SAHA. *PLoS Pathog.* **10**:e1003997. PMID: [PMC3961356](#).
57. Kearney, M.F., J. Spindler, W. Shao, S. Yu, E.M. Anderson, A. O'Shea, C. Rehm, C. Poethke, N. Kovacs, J.W. Mellors, J.M. Coffin, and **F. Maldarelli**. 2014. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. *PLoS Pathog.* **10**:e1004010. PMID: [PMC3961343](#).
58. Bhardwaj, N., **F. Maldarelli**, J. Mellors, and J.M. Coffin. 2014. HIV-1 infection leads to increased transcription of human endogenous retrovirus HERV-K (HML-2) proviruses in vivo but not to increased virion production. *J. Virol.* **88**:11108-11120. PMID: [PMC4178833](#).
59. Sloan, E.A., M.F. Kearney, L.R. Gray, K. Anastos, E.S. Daar, J. Margolick, **F. Maldarelli**, M.L. Hammarskjold, and D. Rekosh. 2013. Limited nucleotide changes in the Rev response element (RRE) during HIV-1 infection alter overall Rev-RRE activity and Rev multimerization. *J. Virol.* **87**:11173-11186. PMID: [PMC3807272](#).
60. Shao, W., V.F. Boltz, J.E. Spindler, M.F. Kearney, **F. Maldarelli**, J.W. Mellors, C. Stewart, N. Volfovsky, A. Levitsky, R.M. Stephens, and J.M. Coffin. 2013. Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of low-frequency drug resistance mutations in HIV-1 DNA. *Retrovirology* **10**:18. PMID: [PMC3599717](#).
61. **Maldarelli, F.**, M. Kearney, S. Palmer, R. Stephens, J. Mican, M.A. Polis, R.T. Davey, J. Kovacs, W. Shao, D. Rock-Kress, J.A. Metcalf, C. Rehm, S.E. Greer, D.L. Lucey, K. Danley, H. Alter, J.W. Mellors, and J.M. Coffin. 2013. HIV populations are large and accumulate high genetic diversity in a nonlinear fashion. *J. Virol.* **87**:10313-10323. PMID: [PMC3754011](#).
62. Josefsson, L., S. Palmer, N.R. Faria, P. Lemey, J. Casazza, D. Ambrozak, M. Kearney, W. Shao, S. Kottlilil, M. Sneller, J. Mellors, J.M. Coffin, and **F. Maldarelli**. 2013. Single cell analysis of lymph node tissue from HIV-1 infected patients reveals that the majority of CD4+ T-cells contain one HIV-1 DNA molecule. *PLoS Pathog.* **9**:e1003432. PMID: [PMC3688524](#).
63. Delviks-Frankenberry, K.A., R.B. Lengruber, A.F. Santos, J.M. Silveira, M.A. Soares, M.F. Kearney, **F. Maldarelli**, and V.K. Pathak. 2013. Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance. *Virology* **435**: 433-441. PMID: [PMC3534945](#).
64. Casazza, J.P., K.A. Bowman, S. Adzaku, E.C. Smith, M.E. Enama, R.T. Bailer, D.A. Price, E. Gostick, I.J. Gordon, D.R. Ambrozak, M.C. Nason, M. Roederer, C.A. Andrews, **F. Maldarelli**, A. Wiegand, M.F. Kearney, D. Persaud, C. Ziemniak, R. Gottardo, J.E. Ledgerwood, B.S. Graham, and R.A. Koup. 2013. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. *J. Infect. Dis.* **207**:1829-1840. PMID: [PMC3654747](#).

65. Andersson, E., W. Shao, I. Bontell, F. Cham, D. Cuong do, A. Wondwossen, L. Morris, G. Hunt, A. Sonnerborg, S. Bertagnolio, **F. Maldarelli**, and M.R. Jordan. 2013. Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. *Infect. Genet. Evol.* **18**:125-131. PMID: [PMC4066879](#).
66. Palmer, S., V.F. Boltz, J.Y. Chow, N.A. Martinson, J.A. McIntyre, G.E. Gray, M.J. Hopley, D. Mayers, P. Robinson, D.B. Hall, **F. Maldarelli**, J.M. Coffin, and J.W. Mellors. 2012. Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women. *Antivir. Ther.* **17**:327-336. PMID: [PMC6752704](#).
67. Kearney, M.F., J. Spindler, A. Wiegand, W. Shao, E.M. Anderson, **F. Maldarelli**, F.W. Ruscetti, J.W. Mellors, S.H. Hughes, S.F. Le Grice, and J.M. Coffin. 2012. Multiple sources of contamination in samples from patients reported to have XMRV infection. *PLoS ONE* **7**:e30889. PMID: [PMC3282701](#).
68. Deeks, S.G., B. Autran, B. Berkhout, M. Benkirane, S. Cairns, N. Chomont, T.W. Chun, M. Churchill, M. Di Mascio, C. Katlama, A. Lafeuillade, A. Landay, M. Lederman, S.R. Lewin, **F. Maldarelli**, D. Margolis, M. Markowitz, J. Martinez-Picado, J.I. Mullins, J. Mellors, S. Moreno, U. O'Doherty, S. Palmer, M.C. Penicaud, M. Peterlin, G. Poli, J.P. Routy, C. Rouzioux, G. Silvestri, M. Stevenson, A. Telenti, C. Van Lint, E. Verdin, A. Woolfrey, J. Zaia, and F. Barre-Sinoussi. 2012. Towards an HIV cure: A global scientific strategy. *Nat. Rev. Immunol.* **12**:607-614. PMID: [PMC3595991](#).
69. Boltz, V.F., Z. Ambrose, M.F. Kearney, W. Shao, V.N. Kewalramani, **F. Maldarelli**, J.W. Mellors, and J.M. Coffin. 2012. Ultrasensitive allele-specific PCR reveals rare preexisting drug-resistant variants and a large replicating virus population in macaques infected with a simian immunodeficiency virus containing human immunodeficiency virus reverse transcriptase. *J. Virol.* **86**:12525-12530. PMID: [PMC3497681](#).
70. Besson, G.J., D. McMahon, **F. Maldarelli**, and J.W. Mellors. 2012. Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. *Clin. Infect. Dis.* **54**:451-453. PMID: [PMC3283111](#).
71. Ananworanich, J., A. Schuetz, C. Vandergeeten, I. Sereti, M. de Souza, R. Rerknimitr, R. Dewar, M. Marovich, F. van Griensven, R. Sekaly, S. Pinyakorn, N. Phanuphak, R. Trichavaroj, W. Rutvisuttinunt, N. Chomchey, R. Paris, S. Peel, V. Valcour, **F. Maldarelli**, N. Chomont, N. Michael, P. Phanuphak, and J.H. Kim on behalf of the RV254/SEARCH 010 Study Group. 2012. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. *PLoS ONE* **7**:e33948. PMID: [PMC3316511](#).
72. Mens, H., M. Kearney, A. Wiegand, J. Spindler, **F. Maldarelli**, J.W. Mellors, and J.M. Coffin. 2011. Amplifying and quantifying HIV-1 RNA in HIV infected individuals with viral loads below the limit of detection by standard clinical assays. *J. Vis. Exp.* **2011**:e2960. PMID: [PMC3230205](#).

73. Kearney, M.F., K. Lee, R.K. Bagni, A. Wiegand, J. Spindler, **F. Maldarelli**, P.A. Pinto, W.M. Linehan, C.D. Vocke, K.A. Delviks-Frankenberry, R.W. Devere White, G.Q. Del Prete, J.W. Mellors, J.D. Lifson, V.N. Kewalramani, V.K. Pathak, J.M. Coffin, and S.F. Le Grice. 2011. Nucleic acid, antibody, and virus culture methods to detect xenotropic MLV- related virus in human blood samples. *Adv. Virol.* **2011**:272193. PMID: [PMC3265299](#).
74. Kearney, M., J. Spindler, W. Shao, **F. Maldarelli**, S. Palmer, S.L. Hu, J.D. Lifson, V.N. KewalRamani, J.W. Mellors, J.M. Coffin, and Z. Ambrose. 2011. Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy. *J. Virol.* **85**:1067-1076. PMID: [PMC3019993](#).
75. Josefsson, L., M.S. King, B. Makitalo, J. Brannstrom, W. Shao, **F. Maldarelli**, M.F. Kearney, W.S. Hu, J. Chen, H. Gaines, J.W. Mellors, J. Albert, J.M. Coffin, and S.E. Palmer. 2011. Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. *Proc. Natl. Acad. Sci.* **108**:11199-11204. PMID: [PMC3131354](#).
76. Ganesan, A., N. Crum-Cianflone, J. Higgins, J. Qin, C. Rehm, J. Metcalf, C. Brandt, J. Vita, C.F. Decker, P. Sklar, M. Bavaro, S. Tasker, D. Follmann, and **F. Maldarelli**. 2011. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. *J. Infect. Dis.* **203**:756-764. PMID: [PMC3071124](#).
77. Dlamini, J.N., Z. Hu, J. Ledwaba, L. Morris, **F.M. Maldarelli**, R.L. Dewar, H.C. Highbarger, H. Somaroo, P. Sangweni, D.A. Follmann, and A.K. Pau. 2011. Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa. *J. Acquir. Immune Defic. Syndr.* **58**:304-308. PMID: [PMC3197956](#).
78. Catalfamo, M., C. Wilhelm, L. Tcheung, M. Proschan, T. Friesen, J.H. Park, J. Adelsberger, M. Baseler, **F. Maldarelli**, R. Davey, G. Roby, C. Rehm, and C. Lane. 2011. CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7. *J. Immunol.* **186**:2106-2116. PMID: [PMC7394280](#).
79. Boyd, S.D., **F. Maldarelli**, I. Sereti, G.L. Ouedraogo, C.A. Rehm, V. Boltz, D. Shoemaker, and A.K. Pau. 2011. Transmitted raltegravir resistance in an HIV-1 CRF\_AG-infected patient. *Antivir. Ther.* **16**:257-261. PMID: [PMC3150494](#).
80. Batorsky, R., M.F. Kearney, S.E. Palmer, **F. Maldarelli**, I.M. Rouzine, and J.M. Coffin. 2011. Estimate of effective recombination rate and average selection coefficient for HIV in chronic infection. *Proc. Natl. Acad. Sci. USA* **108**:5661-5666. PMID: [PMC3078368](#).
81. Aloia, A.L., K.S. Sfanos, W.B. Isaacs, Q. Zheng, **F. Maldarelli**, A.M. De Marzo, and A. Rein. 2010. XMRV: A new virus in prostate cancer? *Cancer Res.* **70**:10028-10033. PMID: [PMC3005136](#).
82. Kutty, G., G. Achaz, **F. Maldarelli**, A. Varma, R. Shroff, S. Becker, G. Fantoni, and J.A. Kovacs. 2010. Characterization of the meiosis-specific recombinase Dmc1 of *Pneumocystis*. *J. Infect. Dis.* **202**:1920-1929. PMID: [PMC3058675](#).

83. Mens, H., M. Kearney, A. Wiegand, W. Shao, K. Schønning, J. Gerstoft, N. Obel, **F. Maldarelli**, J.W. Mellors, T. Benfield, and J.M. Coffin. 2010. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. *J. Virol.* **84**:12971-12981. PMID: [PMC3004307](#).
84. Jordan, M.R., M. Kearney, S. Palmer, W. Shao, **F. Maldarelli**, E.P. Coakley, C. Chappey, C. Wanke, and J.M. Coffin. 2010. Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations. *J. Virol. Methods* **168**:114-120. PMID: [PMC3949620](#).
85. Galli, A., M. Kearney, O.A. Nikolaitchik, S. Yu, M.P.S. Chin, **F. Maldarelli**, J.M. Coffin, V.K. Pathak, and W.-S. Hu. 2010. Patterns of human immunodeficiency virus type 1 recombination ex vivo provide evidence for coadaptation of distant sites, resulting in purifying selection for intersubtype recombinants during replication. *J. Virol.* **84**:7651-7661. PMID: [PMC2897624](#).
86. McMahon, D., J. Jones, A. Wiegand, S.J. Gange, M. Kearney, S. Palmer, S. McNulty, J.A. Metcalf, E. Acosta, C. Rehm, J.M. Coffin, J.W. Mellors, and **F. Maldarelli**. 2010. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. *Clin. Infect. Dis.* **50**:912-919. PMID: [PMC2897152](#).
87. Boltz, V.F., **F. Maldarelli**, N. Martinson, L. Morris, J.A. McIntyre, G. Gray, M.J. Hopley, T. Kimura, D.L. Mayers, P. Robinson, J.W. Mellors, J.M. Coffin, and S.E. Palmer. 2010. Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design. *J. Virol. Methods* **164**:122-126. PMID: [PMC4734888](#).
88. Shao, W., M. Kearney, **F. Maldarelli**, J.W. Mellors, R.M. Stephens, J.D. Lifson, V.N. KewalRamani, Z. Ambrose, J.M. Coffin, and S.E. Palmer. 2009. RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy. *Retrovirology* **6**:101. PMID: [PMC2776578](#).
89. Wilkin, T.J., J.E. McKinnon, A.G. DiRienzo, K. Mollan, C.V. Fletcher, D.M. Margolis, B. Bastow, G. Thal, W. Woodward, C. Godfrey, A. Wiegand, **F. Maldarelli**, S. Palmer, J.M. Coffin, J.W. Mellors, and S. Swindells. 2009. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: Final 48-week clinical and virologic outcomes. *J. Infect. Dis.* **199**:866-871. PMID: [PMC2680942](#).
90. Nies-Kraske, E., T.W. Schacker, D. Condoluci, J. Orenstein, J. Brenchley, C. Fox, M. Daucher, R. Dewar, E. Urban, B. Hill, J. Guenaga, S. Hoover, **F. Maldarelli**, C.W. Hallahan, J. Horn, S. Kottlilil, T.W. Chun, M. Folino, S. Palmer, A. Wiegand, M.A. O'Shea, J.A. Metcalf, D.C. Douek, J. Coffin, A. Haase, A.S. Fauci, and M. Dybul. 2009. Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy. *J. Infect. Dis.* **199**:1648-1656. PMID: [PMC4826569](#).

91. Dinoso, J.B., S.Y. Kim, A.M. Wiegand, S.E. Palmer, S.J. Gange, L. Cranmer, M.A. O'Shea, M. Callender, A. Spivak, T. Brennan, M.F. Kearney, M.A. Proschan, J.M. Mican, C.A. Rehm, J.M. Coffin, J.W. Mellors, R.F. Siliciano, and **F. Maldarelli**. 2009. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. *Proc. Natl. Acad. Sci. USA* **106**:9403-9408. PMID: [PMC2685743](#).
92. Delviks-Frankenberry, K.A., G.N. Nikolenko, **F. Maldarelli**, S. Hase, Y. Takebe, and V.K. Pathak. 2009. Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01\_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine. *J. Virol.* **83**:8502-8513. PMID: [PMC2738196](#).
93. Kearney, M., **F. Maldarelli**, W. Shao, J.B. Margolick, E.S. Daar, J.W. Mellors, V. Rao, J.M. Coffin, and S. Palmer S. 2009. Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. *J. Virol.* **83**:2715-2727. PMID: [PMC2648286](#).
94. Porter, B.O., K.B. Anthony, J. Shen, B. Hahn, C.E. Keh, **F. Maldarelli**, W.C. Blackwelder, H.C. Lane, J.A. Kovacs, R.T. Davey, and I. Sereti. 2009. Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: A randomized controlled trial. *AIDS* **23**:203-212. PMID: [PMC4343197](#).
95. Migueles, S.A., C.M. Osborne, C. Royce, A.A. Compton, R.P. Joshi, K.A. Weeks, J.E. Rood, A.M. Berkley, J.B. Sacha, N.A. Cogliano-Shutta, M. Lloyd, G. Roby, R. Kwan, M. McLaughlin, S. Stallings, C. Rehm, M.A. O'Shea, J. Mican, B.Z. Packard, A. Komoriya, S. Palmer, A.P. Wiegand, **F. Maldarelli**, J.M. Coffin, J.W. Mellors, C.W. Hallahan, D.A. Follman, and M. Connors. 2008. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. *Immunity* **29**:1009-1021. PMID: [PMC2622434](#).
96. Ramanathan, R., A.K. Pau, K.H. Busse, M. Zemskova, L. Nieman, R. Kwan, J.H. Hammer, J.M. Mican, and **F. Maldarelli**. 2008. Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir. *Clin Infect Dis.* **47**:e97-e99. PMID: [PMC2941349](#).
97. Kutty, G., **F. Maldarelli**, G. Achaz, and J.A. Kovacs. 2008. Variation in the major surface glycoprotein genes in *Pneumocystis jirovecii*. *J. Infect. Dis.* **198**:741-749. PMID: [PMC2561252](#).
98. Robertson, S.M., **F. Maldarelli**, V. Natarajan, E. Fomentini, R.M. Alfaro, and S.R.J. Penzak. 2008. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. *J. Acquir. Immune Defic. Syndr.* **49**:513-519. PMID: [18989234](#).
99. Palmer, S., **F. Maldarelli**, A. Wiegand, B. Bernstein, G.J. Hanna, S.C. Brun, D.J. Kempf, J.W. Mellors, J.M. Coffin, and M.S. King. 2008. Low-level viremia persists for at least seven years in patients on suppressive antiretroviral therapy. *Proc. Natl. Acad. Sci. USA* **105**:3879-3884. PMID: [PMC2268833](#).
100. Kearney, M., S. Palmer, **F. Maldarelli**, W. Shao, M.A. Polis, J. Mican, D. Rock-Kress, J.B. Margolick, J.M. Coffin, and J.W. Mellors. 2008. Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. *AIDS* **22**:497-501. PMID: [PMC2921824](#).

101. Ambrose, Z., S. Palmer, V.F. Boltz, M. Kearney, K. Larsen, P. Polacino, L. Flanary, K. Oswald, M. Piatak, Jr., J. Smedley, W. Shao, N. Bischofberger, **F. Maldarelli**, J.T. Kimata, J.W. Mellors, S.L. Hu, J.M. Coffin, J.D. Lifson, and V. KewalRamani. 2007. Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. *J. Virol.* **81**:12145-12155. PMID: [PMC2169021](#).
102. **Maldarelli, F.**, S. Palmer, M.S. King, A. Wiegand, M.A. Polis, J. Mican, J.A. Kovacs, R.T. Davey, D. Rock-Kress, R. Dewar, S. Liu, J.A. Metcalf, C. Rehm, S.C. Brun, G.J. Hanna, D.J. Kempf, J.M. Coffin, and J.W. Mellors. 2007. ART suppresses plasma HIV-1 RNA to a stable set-point predicted by pretherapy viremia. *PLoS Pathog.* **3**:e46. PMID: [PMC1847689](#).
103. Nikolenko, G.N., K.A. Delviks-Frankenberry, S. Palmer, **F. Maldarelli**, M.J. Fivash Jr., J.M. Coffin, and V.K. Pathak. 2007. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance. *Proc. Natl. Acad. Sci. USA* **104**:317-322. PMID: [PMC1765458](#).
104. Palmer, S., V. Boltz, N. Martinson, **F. Maldarelli**, G. Gray, J. McIntyre, J. Mellors, L. Morris, and J.M. Coffin. 2006. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. *Proc. Natl. Acad. Sci. USA* **103**:7094-7099. PMID: [PMC1459023](#).
105. Gafni, R.I., R. Hazra, J.C. Reynolds, **F. Maldarelli**, A.N. Tullio, E. DeCarlo, C.J. Worrell, J.F. Flaherty, K. Yale, B.P. Kearney, and S.L. Zeichner. 2006. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: Impact on bone mineral density in HIV-infected children. *Pediatrics* **118**:e711-718. PMID: [16923923](#).
106. Bashirova, A.A., G. Bleiber, Y. Qi, H. Hutcheson, T. Yamashita, R.C. Johnson, J. Cheng, G. Alter, J.J. Goedert, S. Buchbinder, K. Hoots, D. Vlahov, M. May, **F. Maldarelli**, L. Jacobson, S.J. O'Brien, A. Telenti, and M. Carrington. 2006. Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1. *J. Virol.* **80**:6757-6763. PMID: [PMC1489017](#).
107. Palmer, S., V. Boltz, **F. Maldarelli**, M. Kearney, E.K. Halvas, D. Rock, J. Falloon, R.T. Davey, Jr., R.L. Dewar, J.A. Metcalf, J.W. Mellors, and J.M. Coffin. 2006. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. *AIDS* **20**:701-710. PMID: [16514300](#).
108. Sklar, P.A., H. Masur, J.R. Grubb, J. Voell, J. Witek, A. Ono, E.O. Freed, and **F. Maldarelli**. 2005. Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy. *AIDS* **19**:1109-1111. PMID: [15958846](#).
109. Hazra, R., R.I. Gafni, **F. Maldarelli**, M. Balis, A.N. Tullio, E. DeCarlo, C.J. Worrell, S.M. Steinberg, J. Flaherty, K. Yale, B.P. Kearney, and S.L. Zeichner. 2005. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. *Pediatrics* **16**:846-854. PMID: [16291735](#).

110. Chen, J., Q. Dang, D. Unutmaz, V.K. Pathak, **F. Maldarelli**, D. Powell, and W.-S. Hu. 2005. Mechanisms of nonrandom human immunodeficiency virus type 1 infection and double infection: Preference in virus entry is important but is not the sole factor. *J. Virol.* **79**:4140-4149. PMID: [PMC1061529](#).
111. Palmer, S., M. Kearney, **F. Maldarelli**, E.K. Halvas, C.J. Bixby, H. Bazmi, D. Rock, J. Falloon, R.T. Davey, Jr., R.L. Dewar, J.A. Metcalf, S. Hammer, J.W. Mellors, and J.M. Coffin. 2005. Multiple, linked HIV-1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. *J. Clin. Microbiol.* **43**:406-413. PMID: [PMC540111](#).
112. Nikolenko, G.N., S. Palmer, **F. Maldarelli**, J.W. Mellors, J.M. Coffin, and V.K. Pathak. 2005. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: Balance between RNase H activity and nucleotide excision. *Proc. Natl. Acad. Sci. USA* **102**:2093-2098. PMID: [PMC548555](#).
113. Achaz, G., S. Palmer, M. Kearney, **F. Maldarelli**, J. Mellors, J. Coffin, and J. Wakeley. 2004. A robust measure of HIV-1 population turnover within chronically infected individuals. *Mol. Biol. Evol.* **21**:1902-1912.
114. Janka, J., and **F. Maldarelli**. 2004. Update on prion diseases: Mad cow, variant Creutzfeldt Jakob disease and the transmissible spongiform encephalopathies. *Curr. Infect. Dis. Rep.* **6**:305-313.
115. Dybul, M., E. Nies-Kraske, R. Dewar, **F. Maldarelli**, A. Weigand, S. Palmer, C.W. Hallahan, M. Daucher, S.C. Piscitelli, L. Ehler, J.A. Metcalf, R.T. Davey, D.M. Rock Kress, A. Powers, I. Beck, L. Frenkel, M. Baseler, J. Coffin, and A. S. Fauci. 2004. A proof-of-concept study of short cycle intermittent antiretroviral therapy with a once per day regimen of didanosine, lamivudine and efavirenz for the treatment of chronic HIV infection. *J. Inf. Dis.* **189**:1974-1982.
116. Kottlil, S., S. Jagannatha, A. Lu, S. Liu, M. McLaughlin, J. Metcalf, R. Dewar, C. Ternisky, C. Koratich, **F. Maldarelli**, H. Masur, and M. Polis. 2004. Hepatitis C viral response after initiation of highly active antiretroviral therapy and control of HIV viremia in chronically co-infected individuals. *HIV Clin. Trials* **5**:25-32.
117. Dang, Q., J. Chen, D. Unutmaz, J.M. Coffin, V.K. Pathak, D. Powell, V.N. KewalRamani, **F. Maldarelli**, and W.-S. Hu. 2004. Nonrandom HIV-1 infection and double infection via direct and cell-mediated pathways. *Proc. Natl. Acad. Sci. USA* **101**:632-637. PMID: [PMC327199](#).
118. Palmer, S., A.P. Wiegand, **F. Maldarelli**, H. Bazmi, J.M. Mican, M. Polis, R.L. Dewar, A. Planta, S. Liu, J.A. Metcalf, J.W. Mellors, and J.M. Coffin. 2003. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. *J. Clin. Microbiol.* **41**:4531-4536. PMID: [PMC254331](#).
119. Kottlil, S., T.W. Chun, S. Moir, S. Liu, M. McLaughlin, C.W. Hallahan, **F. Maldarelli**, L. Corey, and A.S. Fauci. 2003. Innate immunity in human immunodeficiency virus infection: Effect of viremia on natural killer cell function. *J. Infect. Dis.* **187**:1038-1045.

120. Favaro, J.P., **F. Maldarelli**, S.J. Arrigo, and M.G. Schmidt. 1999. Effect of Rev on the cytoplasmic localization of intron-containing human immunodeficiency virus type 1 RNA. *Virology* **255**:237-249.
121. Neuveut, C.M., K.G. Low, **F. Maldarelli**, I. Schmitt, F. Majone, R. Grassmann, and K.-T. Jeang. 1998. Human T-cell leukemia virus type 1 Tax and cell cycle progression: Role of cyclin D-cdk and p110Rb. *Mol. Cell. Biol.* **18**:3620-3632. PMID: [PMC108944](#).
122. **Maldarelli, F.**, C. Xiang, G. Chamoun, B. Schilling, and S.L. Zeichner. 1998. The expression of the essential nuclear splicing factor SC35 is altered by human immunodeficiency virus infection. *Virus Res.* **53**:39-51.
123. Hori, K., D. Hatfield, **F. Maldarelli**, B.J. Lee, and K.A. Clouse. 1997. Selenium supplementation suppresses tumor necrosis factor alpha-induced human immuno-deficiency virus type 1 replication in vitro. *AIDS Res. Hum. Retroviruses* **13**:1325-1332.
124. Smith, S.M., **F. Maldarelli**, and K.-T. Jeang. 1997. Efficient expression of a functional ribozyme targeted to HIV-1 using an alphavirus replicon. *J. Virol.* **71**:9713-9721. PMID: [PMC230281](#).
125. Shibata, R., **F. Maldarelli**, C. Seimon, T. Matano, M. Parta, G. Miller, T. Fredrickson, and M.A. Martin. 1997. The extent of CD4 killing and virus loads during primary infections of macaque monkeys is a predictor of the subsequent clinical course. *J. Infect. Dis.* **176**:362-373.
126. Freed, E.O., G. Englund, **F. Maldarelli**, and M.A. Martin. 1997. Phosphorylation of residue 131 of human immunodeficiency virus type 1 matrix is not required for macrophage infection. *Cell* **88**:171-172.
127. Fujita, K., **F. Maldarelli**, and J. Silver. 1996. Bimodal down-regulation of CD4 in cells expressing human immunodeficiency virus type 1 Vpu and Env. *J. Gen. Virol.* **77**:2393-2401.
128. Sorbara, L.R., **F. Maldarelli**, G. Chamoun, B. Shilling, S. Chokekijcahi, L. Staudt, H. Mitsuya, I.A. Simpson, and S.L. Zeichner. 1996. Human immunodeficiency virus type 1 infection of H9 cells induces increased glucose transporter expression. *J. Virol.* **70**: 7275-7279. PMID: [PMC190788](#).
129. Berthold, E., and **F. Maldarelli**. 1996. Cis-acting elements in human immunodeficiency virus type 1 mRNAs direct viral transcripts to distinct intranuclear locations. *J. Virol.* **70**:4667-4682. PMID: [PMC190403](#).
130. Schubert, U., S. Bour, A.V. Ferrer-Montal, M. Montal, **F. Maldarelli**, and K. Strebel. 1996. The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. *J. Virol.* **70**:809-819.
131. **Maldarelli, F.**, H. Sato, E. Berthold, J. Orenstein, and M.A. Martin. 1995. Rapid induction of apoptosis by cell-to-cell transmission of human immunodeficiency virus type 1. *J. Virol.* **69**:6457-6465. PMID: [PMC189546](#).



132. Fujita, K., **F. Maldarelli**, D.F.J. Purcell, and J. Silver. 1994. Murine retroviral vector that induces long-term expression of HIV-1 envelope protein. *J. Virol. Methods* **50**:293-311.
133. **Maldarelli, F.**, M.-Y. Chen, R.L. Willey, K. Strebel. 1993. Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. *J. Virol.* **67**:5056-5061. PMID: [PMC237897](#).
134. Chen, M.-Y., **F. Maldarelli**, M.K. Karczewski, R.L. Willey, and K. Strebel. 1993. Human immunodeficiency virus type 1 Vpu protein induces degradation of CD4 in vitro: The cytoplasmic domain of CD4 contributes to Vpu sensitivity. *J. Virol.* **67**:3877-3884. PMID: [PMC237753](#).
135. Willey, R.L., **F. Maldarelli**, M.A. Martin, and K. Strebel. 1992. Human immuno-deficiency virus type 1 Vpu protein induces rapid degradation of CD4. *J. Virol.* **66**:7193-7200. PMID: [PMC240416](#).
136. Willey, R.L., **F. Maldarelli**, M.A. Martin, and K. Strebel. 1991. Human immuno-deficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. *J. Virol.* **66**:226-234. PMID: [PMC238279](#).
137. **Maldarelli, F.**, M.A. Martin, and K. Strebel. 1991. Identification of posttranscriptionally active inhibitory sequences in human immunodeficiency virus type 1 RNA: Novel level of gene regulation. *J. Virol.* **65**:5732-5743. PMID: [PMC250233](#).
138. Strebel, K., T. Klimkait, **F. Maldarelli**, and M.A. Martin. 1989. Molecular and biochemical analyses of human immunodeficiency virus type 1 *vpu* protein. *J. Virol.* **63**:3784-3791. PMID: [PMC250971](#).
139. **Maldarelli, F.**, N.W. King, Jr., and M.J. Yagi. 1987. Effects of cytoskeletal disrupting agents on mouse mammary tumor virus replication. *Virus Res.* **7**:281-295.
140. **Maldarelli, F.**, and M.J. Yagi. 1986. Reversible suppression of mouse mammary tumor virus replication by prolonged glucocorticoid exposure. *J. Natl. Cancer Inst.* **77**:1109-1115.
141. **Maldarelli, F.**, and M.J. Yagi. 1986. Increased yield of mouse mammary tumor virus (MMTV) by cultivation of monolayer-derived mammary tumor cells in suspension. *In Vitro Cell Dev. Biol.* **22**:542-548.
142. Yagi, M.J., **F. Maldarelli**, S.E. Chin, J.F. Holland, and J.G. Bekesi. 1986. Interference of mouse mammary tumor virus replication by PTT.119 [p-fluoro-L-Phe-m-bis-(2-chloroethyl)-amino-L-Phe-Met ethoxy HCl] — an antitumor agent. *J. Natl. Cancer Inst.* **76**:493-501.
143. **Maldarelli, F.** 1985. Studies of mouse mammary tumor virus composition and replication. Ph.D. thesis, City University of New York.
144. Pitha, P.M., B. Fernie, **F. Maldarelli**, T. Hattman, and N.A. Wivel. 1980. Effect of interferon on mouse leukaemia virus (MuLV). V. Abnormal proteins in virions of Rauscher MuLV produced in the presence of interferon. *J. Gen. Virol.* **46**:97-100.

145. Pitha, P.M., B. Fernie, **F. Maldarelli**, and N.A. Wivel. 1979. The errors in assembly of MuLV in interferon treated cells. *J. Supramol. Struct.* **12**:35-46.
146. Hilton, J., **F. Maldarelli**, and S. Sargent. 1978. Evaluation of the role of isocyanates in the action of therapeutic nitrosoureas. *Biochem. Pharm.* **27**:1359-1363.

Invited Book Chapters, Reviews, and Commentaries:

1. **Maldarelli, F.**, Siliciano, R., and Blankson, J. 2018. HIV biology. In: *Cecil Textbook of Medicine 26<sup>th</sup> Edition* (W. Sheld, et al., eds). Churchill Livingstone, Humana Press.
2. Madeen EP, Maldarelli F, Groopman JD. Environmental Pollutants, Mucosal Barriers, and Pathogen Susceptibility; The Case for Aflatoxin B1 as a Risk Factor for HIV Transmission and Pathogenesis. *Pathogens*. 2021 Sep 23;10(10):1229. doi: 10.3390/pathogens10101229. PMID: 34684180
3. Lange C, Maldarelli F. Immune Reconstitution Following Allogeneic Stem Cell Transplantation in HIV infected Individuals: Years of Living Danger-ously. *Clin Infect Dis*. 2021 Jun 22:ciab565. doi: 10.1093/cid/ciab565. PMID: 34157095
4. **Maldarelli, F.** 2020. The gift of a lifetime: Analysis of HIV at autopsy. *J. Clin. Invest.* **Feb 24**:135905. PMID: [32091411](https://pubmed.ncbi.nlm.nih.gov/32091411/).
5. Simonetti, F., R. Dewar, and **F. Maldarelli**. 2019. Detection of human immunodeficiency virus infection. In: *Principles and Practice of Infectious Diseases* (G.L. Mandell, J.E. Bennett, and R. Dolin, eds.). Churchill Livingstone, Humana Press.
6. **Maldarelli, F.** 2018. HIV biology. In: *Cecil Textbook of Medicine 26<sup>th</sup> Edition* (W. Sheld, et al., eds). Churchill Livingstone, Humana Press.
7. **Maldarelli, F.** 2015. HIV biology. In: *Cecil Textbook of Medicine, 25<sup>th</sup> Edition* (W. Sheld, et al., eds). Churchill Livingstone, Humana Press.
8. Simonetti, F., R. Dewar, and **F. Maldarelli**. 2014. Detection of human immunodeficiency virus infection. In: *Principles and Practice of Infectious Diseases* (G.L. Mandell, J.E. Bennett, and R. Dolin, eds.). Churchill Livingstone, Humana Press.
9. Wiegand, A, and **F. Maldarelli**. 2014. Single-copy quantification of HIV-1 in clinical samples. *Methods Mol. Biol.* **1087**:251-260.
10. Wilson, E., T. Tanzosh, and **F. Maldarelli**. 2013. HIV diagnosis and testing: What every healthcare professional can do (and why they should). *Oral Dis* **19**:431-439.
11. Cortez, K.J., and **F. Maldarelli**. 2011. Clinical management of HIV drug resistance. *Viruses* **3**:347-378. PMCID: [PMC3185705](https://pubmed.ncbi.nlm.nih.gov/3185705/).
12. **Maldarelli, F.** 2011. Targeting viral reservoirs: Ability of antiretroviral therapy to stop viral replication. *Curr. Opin. HIV AIDS* **6**:49-56.
13. Kearney, M., and **F. Maldarelli**. 2010. Editorial commentary: Current status of xenotropic

murine leukemia virus-related retrovirus in chronic fatigue syndrome and prostate cancer: Reach for a scorecard, not a prescription pad. *J. Infect. Dis.* **202**:1463-1466.

14. Dewar, R., D. Goldstein, and **F. Maldarelli**. 2009. Diagnosis of human immuno-deficiency virus infection. In: *Principles and Practice of Infectious Diseases* (G.L. Mandell, J.E. Bennett, and R. Dolin, eds.). Churchill Livingstone.
15. Morse, C., and **F. Maldarelli**. 2008. HIV infection. In: *Immunology, Clinical Case Studies and Disease Pathophysiology* (W. Strober and S. Gottesman, eds.). John Wiley & Sons.

16. Morse, C., and **F. Maldarelli**. 2007. Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: Fitness tampering or a case of persistent braking on entering? *J. Infect. Dis.* **195**:318-321.
17. **Maldarelli, F.** 2006. HIV drug resistance testing. In: *Manual of Pediatric HIV Care* (S. Zeichner and J. Read, eds.). Cambridge University Press.
18. **Maldarelli, F.** 2006. HIV drug resistance. In: *Handbook of Pediatric HIV Care* (S. Zeichner and J. Read, eds.). Cambridge University Press.
19. **Maldarelli, F.** 2006. HIV pathogenesis. In: *Principles of Molecular Medicine* (S. Holland, ed.).
20. **Maldarelli, F.** 2005. Detection of human immunodeficiency virus infection. In: *Principles and Practice of Infectious Diseases* (G.L. Mandell, J.E. Bennett, and R. Dolin, eds.). Churchill Livingstone, Humana Press.
21. Janka, J., and **F. Maldarelli**. 2004. Update on prion diseases: Mad cow, variant Creutzfeldt Jakob disease and the transmissible spongiform encephalopathies. *Curr. Infect. Dis. Rep.* **6**:305-313.
22. **Maldarelli, F.** 2004. HIV drug resistance testing. In: *Manual of Pediatric HIV Care* (S. Zeichner and J. Read, eds.). Cambridge University Press.
23. **Maldarelli, F.** 2004. HIV drug resistance. In: *Handbook of Pediatric HIV Care* (S. Zeichner and J. Read, eds.). Cambridge University Press.
24. **Maldarelli, F.** 2003. HIV-1 fitness and replication capacity: What are they and can they help in patient management? *Curr. Infect. Dis. Rep.* **5**:77-84.
25. **Maldarelli, F.** 2001. Meeting report. First HIV DRP Symposium: Understanding Antiviral Drug Resistance. *Int. Antiviral News* **9**:36-39.